| Patient | Wilma Rudolph |
|---|---|
| Date of birth | 1940-06-23 |
| Identifiers | MRN HR-ML036-SYN-TD; SSN (made up) 000-36-5170 |
| Document date | 1994-10-29 |
| Author | Gloria Haynes-Whitaker, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Periodic adult preventive visit. [S]
Ms. Rudolph is a 54-year-old hospital executive and former Olympic sprinter with an IDH-wildtype, MGMT-methylated glioblastoma of the left frontal lobe, treated with gross total resection and six weeks of radiotherapy with daily temozolomide, who comes for her yearly preventive visit on day 21 of her first adjuvant temozolomide cycle. The MRI three weeks ago showed no progression. She took the five doses of temozolomide without vomiting, using ondansetron before each. She wears the tumor-treating fields device about 19 hours a day; the scalp under the arrays is a little pink but not broken. She is tired by mid-afternoon but works mornings from home. She has had no headache, seizure, change in speech, weakness or fall. Her right hand is back to normal for writing. She walks most days with the cane she keeps for uneven ground. [S]
| Element | Detail |
|---|---|
| Visit | Periodic adult preventive visit, age 54 |
| Glioblastoma | No progression on the post-chemoradiation MRI; adjuvant cycle 1, day 21 |
| Tumor-treating fields | About 19 hours a day; mild scalp redness |
| Mood | PHQ-2 1 |
Health risk assessment. Completed by the patient on the clinic's paper form in the waiting room and reviewed with her by Dr. Haynes-Whitaker. [S]
| Domain | Finding |
|---|---|
| Self-rated health | Fair; tired in the afternoons |
| Psychosocial | Close to her family and friends; still working part days; keeps her spirits up with time with her family and her foundation's young athletes |
| Substance use | No tobacco; no alcohol since surgery; no drug use |
| Physical activity | Walks 20 to 30 minutes most days; home exercises from physical therapy three times a week |
| Nutrition | Appetite fair; eats small meals; weight steady |
| Sleep | Seven to eight hours with the device on; a short nap after lunch |
| Falls and home safety | No falls; grab bars and night lights in place; cane for uneven ground |
| Driving | Not driving since the first symptoms; family and friends drive her |
| Activities of daily living | Independent in all |
| Seat belt and smoke alarms | Always wears a seat belt; smoke alarms tested |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Afternoon fatigue; no fever or weight loss |
| Eyes | Negative | No double or blurred vision |
| Ears, nose, mouth, and throat | Negative | No mouth sores or sore throat |
| Cardiovascular | Negative | No chest pain or leg swelling |
| Respiratory | Negative | No cough or breathlessness |
| Gastrointestinal | Negative | No nausea now, vomiting, diarrhea or constipation |
| Genitourinary | Negative | No urinary symptoms; no vaginal bleeding |
| Breast | Negative | No lump or nipple change |
| Musculoskeletal | Negative | No new weakness, muscle pain or joint pain in either leg |
| Integumentary | Positive | Mild pinkness of the scalp under the device arrays; no blisters or broken skin |
| Neurological | Negative | No headache, seizure, numbness or speech change |
| Hematologic and lymphatic | Negative | No bruising or bleeding |
| Psychiatric | Negative | Mood steady; PHQ-2 1 |
13 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for headache, no more than 3 g a day | Two tablets every 6 hours as needed | Oral route | 1994-06-29 | active | S |
| Dexamethasone 4 mg oral tablet, one tablet twice a day with food, for symptomatic vasogenic edema, until surgery | One tablet twice a day with breakfast and lunch | Oral route | 1994-06-30 to 1994-07-08 | completed | S |
| Famotidine 20 mg oral tablet, one tablet twice a day while taking dexamethasone | One tablet twice a day | Oral route | 1994-06-30 to 1994-08-12 | completed | S |
| Dexamethasone 2 mg oral tablet, one tablet twice a day after surgery, tapering | One tablet twice a day | Oral route | 1994-07-10 to 1994-07-29 | completed | S |
| Dexamethasone 2 mg oral tablet: one tablet daily for one week, then half a tablet daily for one week, then stop | One tablet daily for a week, then half a tablet daily for a week | Oral route | 1994-07-29 to 1994-08-12 | completed | S |
| Temozolomide 140 mg oral capsule, 140 mg (75 mg/m2) by mouth daily at bedtime on an empty stomach, seven days a week for 42 days from the first day of radiotherapy | Once daily at bedtime, seven days a week, for 42 days | Oral route | 1994-08-03 to 1994-09-13 | completed | S |
| Sulfamethoxazole 800 mg and trimethoprim 160 mg oral tablet, one tablet three times a week (Monday, Wednesday and Friday) to prevent Pneumocystis pneumonia | One tablet on Monday, Wednesday and Friday | Oral route | 1994-08-03 | active | S |
| Ondansetron 8 mg oral tablet, one tablet 30 to 60 minutes before each temozolomide dose, and every 8 hours as needed for nausea | Before each temozolomide dose; every 8 hours as needed | Oral route | 1994-08-03 | active | S |
| Temozolomide 140 mg oral capsule, 280 mg (150 mg/m2) by mouth at bedtime on days 1 to 5 of each 28-day cycle, adjuvant cycle 1 of 6 | Two capsules once daily at bedtime on days 1 to 5 of each 28-day cycle | Oral route | 1994-10-09 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1994-10-29 | Body height | 180 | cm | S |
| 1994-10-29 | Body weight | 66.9 | kg | S |
| 1994-10-29 | Body mass index (BMI) [Ratio] | 20.6 | kg/m2 | S |
| 1994-10-29 | Systolic blood pressure | 118 | mm[Hg] | S |
| 1994-10-29 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 1994-10-29 | Heart rate | 76 | /min | S |
| 1994-10-29 | Respiratory rate | 14 | /min | S |
| 1994-10-29 | Body temperature | 36.5 | Cel | S |
| 1994-10-29 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1994-10-29 | Hemoglobin [Mass/volume] in Blood | 11.8 | g/dL | 12-15.5 g/dL | Low | S |
| 1994-10-29 | Leukocytes [#/volume] in Blood by Automated count | 3.4 | 10*3/uL | 4-11 10*3/uL | Low | S |
| 1994-10-29 | Neutrophils [#/volume] in Blood by Automated count | 1.9 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 1994-10-29 | Lymphocytes [#/volume] in Blood by Automated count | 0.6 | 10*3/uL | 1-4 10*3/uL | Low | S |
| 1994-10-29 | Platelets [#/volume] in Blood by Automated count | 121 | 10*3/uL | 150-400 10*3/uL | Low | S |
| 1994-10-29 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 33 | U/L | 7-35 U/L | Normal | S |
| 1994-10-29 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 29 | U/L | 8-35 U/L | Normal | S |
| 1994-10-29 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S |
Vital signs recorded on 1994-10-29; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| Constitutional | Well; weight 66.9 kg; blood pressure 118/72; pulse 76; temperature 36.5 °C |
| Head | Craniotomy incision healed; hair loss over the radiation field; scalp under the arrays mildly pink, intact |
| Mouth | No ulcers or thrush |
| Breasts | Clinical breast examination with a chaperone, at her choice: no masses, skin or nipple changes, or axillary nodes |
| Cardiovascular | Regular rhythm; no murmur |
| Respiratory | Clear |
| Abdomen | Soft, non-tender |
| Extremities | No leg swelling; calves soft and non-tender; left calf slightly smaller than the right, as before |
| Skin | No bruising or petechiae |
| Neurological | Fluent speech; strength full in all four limbs; steady gait; Timed Up and Go 9 seconds |
| Psychiatric | Warm, engaged and direct |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Three weeks of headaches on waking, with ten days of pauses in finding words and clumsiness of the right hand, in a previously well woman of 54: an intracranial lesion must be excluded. MRI of the brain with and without contrast booked for tomorrow morning, and neuro-oncology review booked | resolved | confirmed | R29.818 | S — Synthetic presenting problem; no symptom of her real illness was made public. Superseded when the MRI showed a brain mass. |
| Left posterior frontal ring-enhancing mass, 3.8 cm, with central necrosis, surrounding edema and 5 mm midline shift, next to the language and motor areas; presumed high-grade glioma, with no primary cancer elsewhere on CT; tissue diagnosis pending | resolved | confirmed | D49.6 | S — Synthetic imaging diagnosis before surgery; superseded by the pathology. |
| Glioblastoma, IDH-wildtype, CNS WHO grade 4, left posterior frontal lobe, MGMT promoter methylated, after gross total resection of the enhancing tumor; synthetic modern detail linked to her publicly reported brain cancer | active | confirmed | C71.1 | S — Synthetic histology, molecular result and location; brain cancer is documented as the cause of her death (D), and nothing more about it was made public. |
| Late effects of childhood poliomyelitis: paralysis of the left leg in early childhood, treated with a metal brace, a special shoe, massage and heat, with full recovery of walking by about age 12 and a later career as an Olympic sprinter; no new weakness, fatigue or pain now to suggest post-polio syndrome | active | confirmed | B91 | S — Documented childhood polio (D); the current absence of new symptoms is synthetic. |
| Vasogenic cerebral edema around the left frontal mass, with 5 mm midline shift, causing headache and contributing to the language and right-hand symptoms; treated with dexamethasone | resolved | confirmed | G93.6 | S — Synthetic finding on the first MRI. |
| Steroid-induced hyperglycemia on dexamethasone: random glucose 168 mg/dL, with an A1c of 5.6% before steroids | resolved | confirmed | R73.9 | S — Synthetic common effect of dexamethasone; resolved after the taper. |
| Lymphopenia from temozolomide, grade 2 (absolute lymphocytes 0.5 x 10^3/uL at the end of chemoradiation): Pneumocystis prophylaxis continues until recovery to grade 1 or better | active | confirmed | D72.810 | S — Synthetic common effect of daily temozolomide with radiotherapy. |
Personalized prevention plan. A written copy was given to the patient. [S]
| Service | Status | Detail |
|---|---|---|
| Blood pressure screening | Completed today | 118/72 mmHg |
| Depression screening | Completed today | PHQ-2 score 1; PHQ-9 6 three weeks ago |
| Unhealthy alcohol use screening | Completed today | No alcohol since surgery |
| Tobacco use | Completed today | Never |
| Breast cancer screening | Up to date | Mammogram every two years from 40 to 74; last screening mammogram about a year ago, normal; next to be decided with her when due |
| Cervical cancer screening | Up to date | Cytology with HPV testing about two years ago, negative; next due in about three years |
| Colorectal cancer screening | Up to date | Colonoscopy at 50, normal; next due at 60 |
| Diabetes screening | Up to date | A1c 5.6% before steroids; glucose 91 mg/dL three weeks ago, off steroids |
| Lipid screening | Declined | Declined for now: not drawn today, by her choice, while she is on cancer treatment; to be revisited at the next preventive visit |
| HIV, hepatitis B and hepatitis C screening | Up to date | All negative before temozolomide |
| Osteoporosis screening | Not indicated | Postmenopausal at 54; dexamethasone for under two months and no fracture, so her estimated fracture risk is below the threshold for bone density testing; to be reconsidered if steroids are needed again or she falls |
| Fall risk and mobility | Completed today | No falls; Timed Up and Go 9 seconds; home exercises and home safety measures in place |
| Lung cancer screening | Not indicated | Never smoker |
| Influenza, pneumococcal and zoster vaccines | Completed today | Inactivated influenza vaccine, PCV20 and recombinant zoster dose 1 given today; no live vaccines during chemotherapy |
| COVID-19 vaccine, this season | Due | At her pharmacy, at least a few days apart from the next temozolomide cycle if she prefers |
| Dental and eye examinations | Due | Dental review and an eye examination advised this year |
Immunizations given today: Influenza vaccine, inactivated, trivalent, preservative free, this season; Pneumococcal conjugate vaccine PCV20; Recombinant zoster vaccine, dose 1 of 2 [S]
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers (2026); TEMODAR (temozolomide) capsules, prescribing information (2026); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026); Breast Cancer: Screening (2024); Cervical Cancer: Screening (2018); Colorectal Cancer: Screening (2021); Osteoporosis to Prevent Fractures: Screening (2025); Adult Immunization Schedule by Medical Condition and Other Indication (2026)
Follow-up: Cycle 2 of temozolomide on day 29 with a blood count first. Neuro-oncology review and MRI after cycle 2. Second zoster dose in one to two months; COVID-19 vaccine this season. Next preventive visit in one year. [S]
Voluntary advance care planning discussion of about 20 minutes, with her consent, reviewing the advance directive she completed with the palliative care team last month. She wants treatment aimed at controlling the tumor for as long as it lets her live in a way she values, being at home and with the people she loves, and wants to be told plainly when that balance changes. Her named health care agent is recorded in the confidential part of the chart and is not named here. She asked that information about her health go only to the people she names. To be revisited at each MRI and if her illness changes. [S]